Clinical Commander

Back to dossier
ob.peripartum-cardiomyopathy.v1PRODUCTION
ob.peripartum-cardiomyopathy.v1

Peripartum Cardiomyopathy (PPCM)

obstetricsacutesubacutepregnancyadult
Hard-required inputs
0 / 16
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm PPCM diagnosis (HF developing last month of pregnancy through 5 mo postpartum + EF < 45 % on echo + no other identifiable cause per Pearson 2000 NHLBI; ESC HF 2021 PMID 34447992); distinguish from pre-existing cardiomyopathy, valvular / coronary / congenital disease, severe pre-eclampsia with pulmonary edema, amniotic fluid embolism, pulmonary embolism, sepsis-induced cardiomyopathy, hypertensive emergency with HF

Inputs
3
Actions
0
Advance rule
Set
Advance when

Peripartum window confirmed + EF < 45 % documented + alternative causes considered

Patient inputs (25)

Drives diagnostic window: last month of pregnancy through 5 months postpartum per Pearson 2000 NHLBI; also drives timing-tier-specific regimen (antepartum < 32 wk / antepartum ≥ 32 wk / intrapartum / early postpartum < 1 wk / postpartum 1 wk – 5 mo)

TTN / MYH7 / MYH6 variants identified in ~ 15 % of PPCM (Ware 2016 NEJM); genetic testing referral if positive family history; LR+ ≈ 5 for genetic-substrate predisposition

Recurrence rate 30–50 % if EF not recovered; 15–20 % if recovered (ESC Pregnancy 2018); strongest preconception-counseling indication

ACEi / ARB / ARNI / renin-inhibitor / aliskiren teratogen check (must be held antepartum and during conception planning per ESC Pregnancy 2018); atenolol teratogen check (FGR risk); bromocriptine contraindication check (prior psychiatric / thromboembolic)

Diagnostic anchor (EF < 45 % per Pearson 2000 NHLBI); severity stratification (EF < 35 % → wearable defibrillator consideration; EF < 25 % → bromocriptine consideration window per Hilfiker-Kleiner 2018)

LV thrombus mandates therapeutic anticoagulation (warfarin postpartum / LMWH antepartum; DOACs not validated for valvular / cardioembolic per ESC HF 2021)

LBBB on initial ECG = poorer prognosis (IPAC 2015 PMID 26293760); detects AFib / VT / arrhythmia; QRS > 130 ms + LBBB may eventually drive CRT consideration if EF persistently low

Diagnostic anchor and trajectory marker; > 600 pg/mL diagnostic threshold; > 2000 pg/mL adverse-event-within-30-d threshold (ESC HF 2021)

Rule out concurrent acute coronary syndrome (peripartum AMI / SCAD); modestly elevated in PPCM per IPAC 2015

Baseline + renal function trajectory; guides GDMT titration (ACEi/ARB hold if Cr rising > 30 % per AHA/ACC/HFSA 2022); MRA hold if eGFR < 30 mL/min/1.73 m2

MRA + ACEi monitoring (K > 5.5 mEq/L → hold; AHA/ACC/HFSA 2022)

Cardiogenic shock threshold (SBP < 90) + GDMT titration tolerance (hold beta-blocker or vasodilator if SBP < 90 per ESC HF 2021)

Hypertensive overlap with pre-eclampsia (DBP ≥ 110 → severe HTN per ACOG 767; routes to ob.pre-eclampsia.core.v1)

SpO2 < 94 % + bilateral crackles = pulmonary edema severe feature; bridges to ICU pathway (ESC HF 2021)

Beta-blocker titration target (resting HR 55–70) per AHA/ACC/HFSA 2022; also AFib detection threshold

NYHA II–III drives outpatient GDMT pathway; NYHA III–IV drives inpatient / ICU pathway + delivery-timing acceleration if antepartum (ESC HF 2021)

Rule out concurrent PE / VTE (peripartum baseline VTE risk is high; PPCM further elevates VTE risk via LV stasis)

If antepartum: drives delivery-timing decision + antenatal corticosteroid window (24+0–33+6 wk per ACOG 713 + Roberts Cochrane 2017 PMID 28321847); also drives pregnancy-safe drug selection (hydralazine + nitrates instead of ACEi/ARB)

Pre-eclampsia / HELLP overlap screen — severe HA + visual changes + RUQ pain = pre-eclampsia severe features (routes to ob.pre-eclampsia.core.v1)

Pre-eclampsia history is a PPCM risk factor + raises hypertensive-overlap concern; chronic HTN substrate guides delivery + lactation drug selection

Lactation-compatible HF agents (enalapril, captopril, metoprolol, propranolol, furosemide, warfarin); ARB / spironolactone / SGLT2i caution; bromocriptine REQUIRES lactation cessation (suppresses prolactin)

Hepatic congestion vs pre-eclampsia / HELLP differential (AST/ALT ≥ 2× ULN); also baseline before warfarin or amiodarone

HELLP-overlap criterion (plt < 100 K); also baseline before anticoagulation (LMWH / warfarin)

End-organ perfusion marker; rising lactate → cardiogenic shock pathway + inotropes + MCS evaluation (ESC HF 2021)

LVEDD > 60 mm = poorer prognosis (IPAC 2015 PMID 26293760); guides recovery-trajectory prediction

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (9)

9 need judgement
  • informationallife_threateningppcm_cardiogenic_shock_antepartum
    Antepartum PPCM with cardiogenic shock (SBP < 90 + end-organ hypoperfusion + rising lactate + oliguria) → emergent delivery + ICU + mechanical circulatory support consideration (IABP / Impella / ECMO / VAD); cardiothoracic + OB + anesthesia + neonatology team; ECMO during delivery if needed (ESC HF 2021 PMID 34447992 + ESC Pregnancy 2018 PMID 30165544)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningppcm_with_lv_thrombus
    PPCM with LV mural thrombus on transthoracic or transesophageal echocardiography → therapeutic anticoagulation (warfarin postpartum / LMWH antepartum; DOACs off-label for non-valvular cardioembolic per shared decision); serial echo q4–6 wk to monitor resolution (ESC HF 2021 PMID 34447992)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningppcm_with_arrhythmia_vt_vf
    PPCM with sustained VT / VF or other malignant ventricular arrhythmia → antiarrhythmics (amiodarone — postpartum first; lidocaine acceptable antepartum) + wearable cardioverter-defibrillator + EP consult; risk-stratify for ICD if persistent low EF after 6 mo optimal medical therapy (AHA/ACC/HFSA 2022 PMID 35379503)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningppcm_pulmonary_edema_antepartum_decompensated
    Antepartum PPCM with decompensated pulmonary edema (SpO2 < 94 % + bilateral crackles + tachypnea + dyspnea on minimal exertion) → IV diuretics + nitrates (if BP permits) + early-delivery consideration; routes to OB / MFM for delivery planning + anesthesia for hemodynamic management; CAUTIOUS diuresis to avoid placental hypoperfusion (ESC HF 2021 + ESC Pregnancy 2018 PMID 30165544)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereppcm_severe_lv_dysfunction_ef_below_35
    PPCM with severe LV dysfunction (EF < 35 %) — bridge medical therapy + wearable cardioverter-defibrillator (LifeVest) consideration during first 3–6 mo of GDMT + cardiology + monitor for recovery × 6 mo before ICD evaluation (AHA/ACC/HFSA 2022 PMID 35379503)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereppcm_overlap_with_pre_eclampsia_or_hellp
    PPCM with concurrent pre-eclampsia (severe features) or HELLP syndrome → combined management; pre-eclampsia management drives delivery decision (ACOG 222); cardiology coordinates HF medications avoiding teratogenic combinations; magnesium for pre-eclampsia severe features still indicated but monitor for synergistic hypotension with afterload reduction in PPCM (ESC Pregnancy 2018 + ACOG 222 + Magpie 2002 PMID 12057549)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereppcm_subsequent_pregnancy_recurrence_risk
    Subsequent pregnancy planning after prior PPCM → preconception MFM + cardiology consultation; recurrence 30–50 % if EF not fully recovered (≥ 50 %); 15–20 % if EF recovered; baseline echo + NT-proBNP + stress test; close surveillance from first trimester; some specialists advise against pregnancy if EF not recovered (ESC Pregnancy 2018 PMID 30165544; ESC HF 2021 PMID 34447992)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereppcm_recovery_failure_at_12_months
    PPCM with EF persistently < 35 % at 12 mo despite optimal GDMT (maximum tolerated ACEi/ARNI + beta-blocker + MRA + SGLT2i + lifestyle) → advanced HF evaluation including transplant referral + VAD evaluation + ICD; pregnancy contraindication counseling; advanced HF center referral if not already (AHA/ACC/HFSA 2022 PMID 35379503 + ESC HF 2021 PMID 34447992)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateppcm_postpartum_bromocriptine_consideration
    Early postpartum (< 2 wk) PPCM + EF < 25 % or cardiogenic shock + willing to cease lactation + no contraindication (psychiatric history, prior thromboembolism, severe HTN) → bromocriptine 2.5 mg PO BID × 1 wk (short-course IPAC-style) OR × 2 wk then 2.5 mg daily × 6 wk (8-week regimen) as adjunct to standard HF therapy; mandatory concurrent enoxaparin VTE prophylaxis; lactation cessation required; per Hilfiker-Kleiner 2018 Eur Heart J + ESC HF 2021 class IIa; AHA/ACC/HFSA 2022 class IIb — not standard of care in US but considered in select cases per shared decision
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives severity classification
Loading…

Recommended regimen

Peripartum cardiomyopathy — timing-tier-and-severity-driven (antepartum pregnancy-safe regimen → intrapartum hemodynamic management → postpartum full GDMT; anticoagulation + bromocriptine consideration + wearable defibrillator / ICD per severity tier)
axis: ppcm_timing_and_severity_drivenstep 1 - Tier 1 — Antepartum pregnancy-safe HF regimen (hydralazine + nitrates + beta-blocker + cautious diuresis) (ESC Pregnancy 2018 PMID 30165544)
Selected step "Tier 1 — Antepartum pregnancy-safe HF regimen (hydralazine + nitrates + beta-blocker + cautious diuresis) (ESC Pregnancy 2018 PMID 30165544)" — Antepartum PPCM at any GA (< 32 wk or ≥ 32 wk) + stable to severe (NYHA II–IV) + no cardiogenic shock
  • hydralazine
    first line
    arterial_vasodilator
    10–25 mg PO TID-QID; titrate to 25–100 mg PO QID (max ~ 300 mg/day); IV 5–10 mg q20min for acute severe HTN • PO / IV • TID-QID
    triggers: antepartum_ppcm, aceI_arb_contraindicated_in_pregnancy
    ESC Pregnancy 2018 — pregnancy-safe arterial vasodilator; combine with nitrates for afterload + preload reduction; ACEi/ARB/ARNI/renin inhibitor contraindicated antepartum (fetal renal dysplasia / oligohydramnios / neonatal hypotension)
    rxcui 5470
  • isosorbide dinitrate
    first line
    venodilator_nitrate
    10–20 mg PO TID; titrate to 40 mg PO TID (allow nitrate-free interval); IV nitroglycerin 5–20 mcg/min titrated for acute pulmonary edema • PO / IV • TID
    triggers: antepartum_ppcm, preload_reduction_needed
    ESC Pregnancy 2018 — pregnancy-safe venodilator; combined with hydralazine substitutes for ACEi/ARB in pregnancy (V-HeFT vintage regimen + A-HeFT in African-American HFrEF cohort)
    rxcui 6058
  • carvedilol
    first line
    mixed_alpha_beta_blocker
    3.125 mg PO BID; titrate q2 wk to 25 mg PO BID (or 50 mg BID if > 85 kg); HOLD if SBP < 90 or HR < 55 • PO • BID
    triggers: antepartum_ppcm, postpartum_ppcm, gdmt_beta_blocker_selection
    AHA/ACC/HFSA 2022 + ESC HF 2021 — first-line beta-blocker for HFrEF; pregnancy-acceptable per ESC Pregnancy 2018 (avoid atenolol due to FGR risk per NICE 2019)
    rxcui 20352
  • metoprolol succinate
    first line
    cardioselective_beta_blocker
    12.5–25 mg PO daily; titrate q2 wk to 200 mg PO daily; HOLD if SBP < 90 or HR < 55 • PO • daily
    triggers: antepartum_ppcm, postpartum_ppcm, carvedilol_intolerance
    AHA/ACC/HFSA 2022 + ESC HF 2021 — first-line beta-blocker for HFrEF; pregnancy-acceptable; lactation-compatible (low transfer)
    rxcui 866412
  • bisoprolol
    second line
    cardioselective_beta_blocker
    1.25 mg PO daily; titrate q2 wk to 10 mg PO daily; HOLD if SBP < 90 or HR < 55 • PO • daily
    triggers: carvedilol_metoprolol_intolerance
    ESC HF 2021 — alternative cardioselective beta-blocker; pregnancy-acceptable per ESC Pregnancy 2018
    rxcui 19484
  • furosemide
    first line
    loop_diuretic
    20–40 mg PO/IV BID; titrate to symptomatic euvolemia; cautious dosing antepartum to avoid placental hypoperfusion • PO / IV • BID-TID
    triggers: ppcm_with_volume_overload, pulmonary_edema
    ESC HF 2021 + AHA/ACC/HFSA 2022 — preferred loop diuretic in pregnancy and lactation; cautious antepartum dosing per ESC Pregnancy 2018
    rxcui 4603

outpatient playbook — drug actions (3)

  1. 1. Continue + uptitrate full GDMT (ACEi/ARNI + beta-blocker + MRA + SGLT2i)
    Enalapril 5 → 20 mg BID OR sacubitril-valsartan 24/26 → 97/103 mg BID (if not breastfeeding); carvedilol 6.25 → 25 mg BID OR metoprolol succinate 25 → 200 mg daily; spironolactone 12.5 → 25 mg daily; empagliflozin or dapagliflozin 10 mg daily (after lactation cessation) • PO • titrated
    trigger: Postpartum outpatient management
    AHA/ACC/HFSA 2022 + ESC HF 2021 — maximum tolerated GDMT
  2. 2. Continue anticoagulation if LV thrombus or EF < 30–35 % with risk factor
    Warfarin INR 2–3 OR apixaban 5 mg BID off-label • PO • daily / BID
    trigger: Persistent LV thrombus or EF threshold
    ESC HF 2021
  3. 3. Highly-effective contraception during recovery
    IUD or etonogestrel implant per OB protocol • intrauterine / subdermal • in situ
    trigger: Sexually active + EF < 50 % during recovery
    WHO MEC + ESC Pregnancy 2018 — avoid combined estrogen contraception if EF < 50 %

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: New dyspnea / orthopnea / paroxysmal nocturnal dyspnea in last month of pregnancy through 5 months postpartum (Pearson 2000 NHLBI; ESC HF 2021 PMID 34447992); New / progressive lower-extremity edema disproportionate to expected pregnancy / postpartum baseline (ESC HF 2021); Transthoracic echocardiogram showing EF < 45 % in peripartum window with no other identifiable cause (Pearson 2000 NHLBI).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Peripartum Cardiomyopathy (PPCM)** (ob.peripartum-cardiomyopathy.v1).
Phenotype framing: Phenotype: PPCM (Pearson 2000 NHLBI confirmed) vs pre-existing cardiomyopathy vs takotsubo / stress cardiomyopathy vs viral myocarditis vs pulmonary embolism vs amniotic fluid embolism vs pre-eclampsia with pulmonary edema vs sepsis-induced cardiomyopathy vs peripartum AMI / SCAD vs hypertensive emergency with HF; assign timing tier (antepartum < 32 wk / antepartum ≥ 32 wk / intrapartum / early postpartum < 1 wk / postpartum 1 wk – 5 mo); assign severity tier (mild-moderate EF 35–44 / severe EF < 35 / cardiogenic shock)
Scope: Confirm PPCM diagnosis (HF developing last month of pregnancy through 5 mo postpartum + EF < 45 % on echo + no other identifiable cause per Pearson 2000 NHLBI; ESC HF 2021 PMID 34447992); distinguish from pre-existing cardiomyopathy, valvular / coronary / congenital disease, severe pre-eclampsia with pulmonary edema, amniotic fluid embolism, pulmonary embolism, sepsis-induced cardiomyopathy, hypertensive emergency with HF

No severity triggers fired against current inputs.

Plan

Regimen axis: **Peripartum cardiomyopathy — timing-tier-and-severity-driven (antepartum pregnancy-safe regimen → intrapartum hemodynamic management → postpartum full GDMT; anticoagulation + bromocriptine consideration + wearable defibrillator / ICD per severity tier)** — step "Tier 1 — Antepartum pregnancy-safe HF regimen (hydralazine + nitrates + beta-blocker + cautious diuresis) (ESC Pregnancy 2018 PMID 30165544)".
1. hydralazine 10–25 mg PO TID-QID; titrate to 25–100 mg PO QID (max ~ 300 mg/day); IV 5–10 mg q20min for acute severe HTN PO / IV TID-QID (arterial_vasodilator, first line) — ESC Pregnancy 2018 — pregnancy-safe arterial vasodilator; combine with nitrates for afterload + preload reduction; ACEi/ARB/ARNI/renin inhibitor contraindicated antepartum (fetal renal dysplasia / oligohydramnios / neonatal hypotension)
2. isosorbide dinitrate 10–20 mg PO TID; titrate to 40 mg PO TID (allow nitrate-free interval); IV nitroglycerin 5–20 mcg/min titrated for acute pulmonary edema PO / IV TID (venodilator_nitrate, first line) — ESC Pregnancy 2018 — pregnancy-safe venodilator; combined with hydralazine substitutes for ACEi/ARB in pregnancy (V-HeFT vintage regimen + A-HeFT in African-American HFrEF cohort)
3. carvedilol 3.125 mg PO BID; titrate q2 wk to 25 mg PO BID (or 50 mg BID if > 85 kg); HOLD if SBP < 90 or HR < 55 PO BID (mixed_alpha_beta_blocker, first line) — AHA/ACC/HFSA 2022 + ESC HF 2021 — first-line beta-blocker for HFrEF; pregnancy-acceptable per ESC Pregnancy 2018 (avoid atenolol due to FGR risk per NICE 2019)
4. metoprolol succinate 12.5–25 mg PO daily; titrate q2 wk to 200 mg PO daily; HOLD if SBP < 90 or HR < 55 PO daily (cardioselective_beta_blocker, first line) — AHA/ACC/HFSA 2022 + ESC HF 2021 — first-line beta-blocker for HFrEF; pregnancy-acceptable; lactation-compatible (low transfer)
5. bisoprolol 1.25 mg PO daily; titrate q2 wk to 10 mg PO daily; HOLD if SBP < 90 or HR < 55 PO daily (cardioselective_beta_blocker, second line) — ESC HF 2021 — alternative cardioselective beta-blocker; pregnancy-acceptable per ESC Pregnancy 2018
6. furosemide 20–40 mg PO/IV BID; titrate to symptomatic euvolemia; cautious dosing antepartum to avoid placental hypoperfusion PO / IV BID-TID (loop_diuretic, first line) — ESC HF 2021 + AHA/ACC/HFSA 2022 — preferred loop diuretic in pregnancy and lactation; cautious antepartum dosing per ESC Pregnancy 2018

Setting playbook (outpatient) — Serial echocardiography q3 mo × 12 mo (or sooner if worsening); GDMT uptitration to maximum tolerated doses; ICD evaluation only after ≥ 6 mo optimal medical therapy if EF persistently < 35 % per AHA/ACC/HFSA 2022 PMID 35379503; preconception MFM + cardiology consultation if planning next pregnancy with recurrence-risk counseling (30–50 % if EF not recovered, 15–20 % if recovered) per ESC Pregnancy 2018; lifelong cardiology surveillance even after recovery; psychosocial monitoring (PPD / PTSD risk) with referral as needed
7. Continue + uptitrate full GDMT (ACEi/ARNI + beta-blocker + MRA + SGLT2i) Enalapril 5 → 20 mg BID OR sacubitril-valsartan 24/26 → 97/103 mg BID (if not breastfeeding); carvedilol 6.25 → 25 mg BID OR metoprolol succinate 25 → 200 mg daily; spironolactone 12.5 → 25 mg daily; empagliflozin or dapagliflozin 10 mg daily (after lactation cessation) PO titrated — Postpartum outpatient management (AHA/ACC/HFSA 2022 + ESC HF 2021 — maximum tolerated GDMT)
8. Continue anticoagulation if LV thrombus or EF < 30–35 % with risk factor Warfarin INR 2–3 OR apixaban 5 mg BID off-label PO daily / BID — Persistent LV thrombus or EF threshold (ESC HF 2021)
9. Highly-effective contraception during recovery IUD or etonogestrel implant per OB protocol intrauterine / subdermal in situ — Sexually active + EF < 50 % during recovery (WHO MEC + ESC Pregnancy 2018 — avoid combined estrogen contraception if EF < 50 %)

Non-pharmacologic actions:
- Cardiology follow-up q3 mo × 12 mo then q6 mo if recovered; lifelong if EF < 50 %
- OB postpartum follow-up per ACOG 222 + ACOG 2025 (3–7 d, 1–2 wk, 4–6 wk, 6-week comprehensive visit)
- Serial echocardiography q3 mo × 12 mo or sooner if worsening
- Symptom education + return precautions (ESC HF 2021)
- Daily weights + symptom log at home (AHA HF 2022)
- Sodium restriction 2 g/day + fluid restriction 1.5–2 L/day in HFrEF
- EPDS / PPD screen at each visit during postpartum year with perinatal mental health referral if positive (psych.postpartum-depression.v1 overlay)
- Preconception MFM + cardiology consultation if planning next pregnancy; baseline echo + NT-proBNP + stress test; recurrence-risk counseling
- Highly-effective contraception during recovery phase (IUD, etonogestrel implant)
- Genetic testing referral if family history of cardiomyopathy
- Vaccination review (flu, Tdap, COVID, RSV)
- Cardiac rehabilitation referral once stable (AHA HF 2022)

AVOID / contraindication checks:
- Never ACE ARB ARNI renin inhibitor in pregnancy antepartum (ESC Pregnancy 2018)
- Never aliskiren in pregnancy (ESC Pregnancy 2018)
- Avoid atenolol pregnancy FGR risk (NICE 2019)
- Never methylergonovine in PPCM (ESC Pregnancy 2018 + ACOG 2020)
- Nitroprusside caution cyanide toxicity after 4h (ACOG 767)
- NSAIDs avoid in HFrEF (AHA HF 2022)
- VTE prophylaxis with enoxaparin during bromocriptine course (Hilfiker Kleiner 2018)
- Lactation cessation required with bromocriptine (Hilfiker Kleiner 2018)
- DOACs not validated for cardioembolic or valvular in pregnancy use LMWH antepartum warfarin postpartum (ESC HF 2021)
- SGLT2i not recommended in pregnancy or lactation hold antepartum and during lactation (manufacturer cautions)
- MRA antepartum limited safety data prefer postpartum (ESC Pregnancy 2018)
- ICD only after 6 months optimal medical therapy if EF persistently below 35 (AHA HF 2022)
- Combined estrogen contraception avoid in EF below 50 use IUD or etonogestrel (WHO MEC)
- Check VTE prophylaxis when antepartum admitted plt above 70 to 80 for neuraxial (SOAP Bauer 2021 PMID 33861047)
- Avoid bolus oxytocin in PPCM titrate to avoid vasodilation (ESC Pregnancy 2018)

Monitoring

Regimen monitoring:
- Echo q3 mo x 12 mo or sooner if worsening (ESC HF 2021)
- NT-proBNP weekly during titration then q3 mo (ESC HF 2021)
- BP HR weekly during titration then per cardiology visit (AHA HF 2022)
- Daily weights + symptom log (AHA HF 2022)
- BMP q3 to 5 d during ACEi or MRA titration then q3 mo (AHA HF 2022)
- INR weekly if warfarin (ESC HF 2021)
- Anti-Xa peak 0.5 to 1.0 IU per mL if therapeutic LMWH (ESC Pregnancy 2018)
- LV thrombus serial echo q4 to 6 wk if therapeutic anticoagulation (ESC HF 2021)
- Fetal monitoring NST BPP per ACOG 222 if antepartum
- Lactation medication review q visit if breastfeeding (ESC Pregnancy 2018)
- Postpartum BP daily x 1 wk weekly x 6 wk if pre-eclampsia overlap (ACOG 222 + AHA 2021)
- 6 week postpartum comprehensive visit (ACOG 2025)
- EPDS or PPD screen q visit during postpartum year (ACOG 736 + psych.postpartum-depression.v1 overlay)

Setting (outpatient) monitoring:
- Echo q3 mo × 12 mo + thereafter q6 mo if recovered
- NT-proBNP q1–2 wk during titration then q3 mo
- BP HR weekly during titration then per cardiology visit
- BMP q3–5 d during ACEi/MRA titration then q3 mo
- INR weekly if warfarin (transition to home INR monitoring per local protocol)
- EPDS / PPD q visit during postpartum year
- Annual CV-risk screening lifelong post-PPCM

Follow-up plan: Cardiology q3 mo × 12 mo + thereafter q6 mo if recovered; serial echocardiography q3 mo × 12 mo (or sooner if worsening); GDMT uptitration to maximum tolerated; ICD evaluation only after ≥ 6 mo optimal medical therapy if EF persistently < 35 % per AHA/ACC/HFSA 2022 PMID 35379503; advanced HF / transplant referral if no recovery at 12 mo; preconception MFM + cardiology consultation if planning next pregnancy with recurrence-risk counseling (30–50 % if EF not recovered, 15–20 % if recovered); highly-effective contraception during recovery (IUD, etonogestrel implant; avoid combined estrogen contraceptives in EF < 50 % per WHO MEC); EPDS / PPD screen + perinatal mental health referral as needed (psych.postpartum-depression.v1 overlay); psychosocial + family counseling
- Close-out criterion: Recovery trajectory documented; GDMT optimized; preconception counseling complete if planning next pregnancy; long-term cardiology surveillance established

Monitoring phase: Serial echocardiography q3 mo × 12 mo (or sooner if worsening); NT-proBNP trajectory q1–2 wk during titration then q3 mo; daily weights + symptom log; renal + K+ q3–5 d during ACEi/MRA titration then q3 mo; LV thrombus surveillance q4–6 wk if on therapeutic anticoagulation; INR weekly if warfarin; lactation-medication review q visit; postpartum BP monitoring if pre-eclampsia overlap (ACOG 222 + AHA 2021); 6-week postpartum comprehensive visit (ACOG 2025)

Disposition

Current setting: outpatient — Serial echocardiography q3 mo × 12 mo (or sooner if worsening); GDMT uptitration to maximum tolerated doses; ICD evaluation only after ≥ 6 mo optimal medical therapy if EF persistently < 35 % per AHA/ACC/HFSA 2022 PMID 35379503; preconception MFM + cardiology consultation if planning next pregnancy with recurrence-risk counseling (30–50 % if EF not recovered, 15–20 % if recovered) per ESC Pregnancy 2018; lifelong cardiology surveillance even after recovery; psychosocial monitoring (PPD / PTSD risk) with referral as needed

Disposition criteria:
- Outpatient cardiology + OB postpartum f/u acceptable for stable mild-moderate postpartum on GDMT with no overlays (ESC HF 2021)
- 12-month follow-up: EF recovery to ≥ 50 % → continue GDMT at maximum tolerated; lifelong CV surveillance; preconception planning if applicable
- No recovery at 12 mo + EF persistently < 35 % → advanced HF + transplant + ICD evaluation per AHA HF 2022

Escalation triggers (move to higher acuity):
- Worsening NYHA class or symptoms → urgent cardiology + echo + NT-proBNP
- EF declines on serial echo → uptitrate GDMT + consider MCS evaluation + advanced HF referral
- New LV thrombus on echo → therapeutic anticoagulation
- New AFib or sustained ventricular arrhythmia → cardiology / EP + anticoagulation review
- EF persistently < 35 % after ≥ 6 mo optimal GDMT → ICD evaluation (AHA HF 2022 class I)
- No EF recovery at 12 mo → advanced HF + transplant evaluation
- Postpartum severe HTN ≥ 160/110 within 6 wk → ED for IV antihypertensive + magnesium prophylaxis (AHA 2021 + ACOG 222)
- Subsequent pregnancy planning → preconception MFM + cardiology consultation; advise against pregnancy if EF not recovered per shared decision

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Antepartum PPCM with cardiogenic shock (SBP < 90 + end-organ hypoperfusion + rising lactate + oliguria) → emergent delivery + ICU + mechanical circulatory support consideration (IABP / Impella / ECMO / VAD); cardiothoracic + OB + anesthesia + neonatology team; ECMO during delivery if needed (ESC HF 2021 PMID 34447992 + ESC Pregnancy 2018 PMID 30165544)
- [LIFE_THREATENING] PPCM with LV mural thrombus on transthoracic or transesophageal echocardiography → therapeutic anticoagulation (warfarin postpartum / LMWH antepartum; DOACs off-label for non-valvular cardioembolic per shared decision); serial echo q4–6 wk to monitor resolution (ESC HF 2021 PMID 34447992)
- [LIFE_THREATENING] PPCM with sustained VT / VF or other malignant ventricular arrhythmia → antiarrhythmics (amiodarone — postpartum first; lidocaine acceptable antepartum) + wearable cardioverter-defibrillator + EP consult; risk-stratify for ICD if persistent low EF after 6 mo optimal medical therapy (AHA/ACC/HFSA 2022 PMID 35379503)

Citations

- ESC Heart Failure 2021 (McDonagh et al, Eur Heart J 2021) + AHA/ACC/HFSA Heart Failure 2022 (Heidenreich et al, JACC 2022) + ESC Pregnancy 2018 (Regitz-Zagrosek et al, Eur Heart J 2018) + IPAC trial 2015 (McNamara et al, JACC 2015) + Hilfiker-Kleiner 2018 Eur Heart J bromocriptine multicentre randomized + EURObservational PPCM Registry (Sliwa et al, Eur Heart J 2020) + Pearson 2000 NHLBI diagnostic criteria + ACOG 222 (2020, reaff 2024) + ACOG 767 (2017, reaff 2020) + ACOG 713 antenatal corticosteroids (2017) + Roberts Cochrane antenatal steroids 2017 + Liggins 1972 + DAPA-HF NEJM 2019 + EMPEROR-Reduced NEJM 2020 + Magpie Lancet 2002 + WHO MEC contraception [PMID:34447992](https://pubmed.ncbi.nlm.nih.gov/34447992/)
- Cited evidence (PMID 35379503) [PMID:35379503](https://pubmed.ncbi.nlm.nih.gov/35379503/)
- Cited evidence (PMID 30165544) [PMID:30165544](https://pubmed.ncbi.nlm.nih.gov/30165544/)
- Cited evidence (PMID 26293760) [PMID:26293760](https://pubmed.ncbi.nlm.nih.gov/26293760/)
- Cited evidence (PMID 28321847) [PMID:28321847](https://pubmed.ncbi.nlm.nih.gov/28321847/)

Last reconciled with current guidelines: 2026-05-25.
References
  • ESC Heart Failure 2021 (McDonagh et al, Eur Heart J 2021) + AHA/ACC/HFSA Heart Failure 2022 (Heidenreich et al, JACC 2022) + ESC Pregnancy 2018 (Regitz-Zagrosek et al, Eur Heart J 2018) + IPAC trial 2015 (McNamara et al, JACC 2015) + Hilfiker-Kleiner 2018 Eur Heart J bromocriptine multicentre randomized + EURObservational PPCM Registry (Sliwa et al, Eur Heart J 2020) + Pearson 2000 NHLBI diagnostic criteria + ACOG 222 (2020, reaff 2024) + ACOG 767 (2017, reaff 2020) + ACOG 713 antenatal corticosteroids (2017) + Roberts Cochrane antenatal steroids 2017 + Liggins 1972 + DAPA-HF NEJM 2019 + EMPEROR-Reduced NEJM 2020 + Magpie Lancet 2002 + WHO MEC contraception — PMID:34447992
  • Cited evidence (PMID 35379503) — PMID:35379503
  • Cited evidence (PMID 30165544) — PMID:30165544
  • Cited evidence (PMID 26293760) — PMID:26293760
  • Cited evidence (PMID 28321847) — PMID:28321847